DNIB Unwind (NASDAQ: BIND) is one of 95 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare DNIB Unwind to related businesses based on the strength of its earnings, valuation, dividends, institutional ownership, analyst recommendations, risk and profitability.


This table compares DNIB Unwind and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DNIB Unwind -201.34% -3,980.56% -123.62%
DNIB Unwind Competitors -910.58% -183.99% -27.07%

Analyst Ratings

This is a summary of current recommendations for DNIB Unwind and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DNIB Unwind 0 0 0 0 N/A
DNIB Unwind Competitors 122 463 1157 11 2.60

As a group, “Biotechnology” companies have a potential upside of 56.08%. Given DNIB Unwind’s peers higher probable upside, analysts clearly believe DNIB Unwind has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares DNIB Unwind and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
DNIB Unwind N/A N/A -0.44
DNIB Unwind Competitors $224.52 million $58.08 million -1.13

DNIB Unwind’s peers have higher revenue and earnings than DNIB Unwind. DNIB Unwind is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

DNIB Unwind has a beta of 2.79, meaning that its share price is 179% more volatile than the S&P 500. Comparatively, DNIB Unwind’s peers have a beta of 1.13, meaning that their average share price is 13% more volatile than the S&P 500.

Insider & Institutional Ownership

20.4% of shares of all “Biotechnology” companies are held by institutional investors. 19.6% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


DNIB Unwind peers beat DNIB Unwind on 6 of the 8 factors compared.

DNIB Unwind Company Profile

DNIB Unwind, Inc., formerly BIND Therapeutics, Inc. is a shell company. The Company was engaged in developing targeted therapeutics, primarily for the treatment of cancer. As of August 1, 2016, the Company sold all of its assets. The Company’s subsidiaries include BIND (RUS) LLC and DNIB Subsidiary Corporation.

Receive News & Ratings for DNIB Unwind Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DNIB Unwind Inc and related companies with MarketBeat.com's FREE daily email newsletter.